T. Rowe Price Associates
CNMD icon

T. Rowe Price Associates’s CONMED CNMD Stock Holding History

T. Rowe Price Associates’s Portfolio CNMD Stock Details CNMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.28M Sell
36,088
-122,640
-77% -$4.99M ﹤0.01% 2027
2025
Q4 		$6.45M Buy
158,728
+4,172
+3% +$181K ﹤0.01% 1324
2025
Q3 		$7.27M Buy
154,556
+1,270
+0.8% +$65.8K ﹤0.01% 1304
2025
Q2 		$7.98M Buy
153,286
+1,925
+1% +$106K ﹤0.01% 1161
2025
Q1 		$9.14M Buy
151,361
+1,691
+1% +$109K ﹤0.01% 1130
2024
Q4 		$10.2M Buy
149,670
+3,260
+2% +$227K ﹤0.01% 1147
2024
Q3 		$10.5M Sell
146,410
-34,600
-19% -$2.44M ﹤0.01% 1133
2024
Q2 		$12.5M Sell
181,010
-14,624
-7% -$1.07M ﹤0.01% 1067
2024
Q1 		$15.7M Sell
195,634
-102,704
-34% -$9.15M ﹤0.01% 1033
2023
Q4 		$32.7M Sell
298,338
-2,899
-1% -$300K ﹤0.01% 824
2023
Q3 		$30.4M Buy
301,237
+6,323
+2% +$727K ﹤0.01% 817
2023
Q2 		$40.1M Buy
294,914
+62,747
+27% +$7.66M 0.01% 764
2023
Q1 		$24.1M Sell
232,167
-40,603
-15% -$3.93M ﹤0.01% 871
2022
Q4 		$24.2M Buy
272,770
+307
+0.1% +$25.5K ﹤0.01% 862
2022
Q3 		$21.8M Buy
272,463
+1,915
+0.7% +$181K ﹤0.01% 878
2022
Q2 		$25.9M Buy
270,548
+2,187
+0.8% +$262K ﹤0.01% 1101
2022
Q1 		$39.9M Buy
268,361
+1,419
+0.5% +$198K ﹤0.01% 1047
2021
Q4 		$37.8M Buy
266,942
+20,226
+8% +$2.86M ﹤0.01% 1097
2021
Q3 		$32.3M Buy
246,716
+27,437
+13% +$3.59M ﹤0.01% 1162
2021
Q2 		$30.1M Buy
219,279
+207,896
+1,826% +$28.5M ﹤0.01% 1199
2021
Q1 		$1.49M Sell
11,383
-3,102
-21% -$373K ﹤0.01% 1854
2020
Q4 		$1.62M Sell
14,485
-103
-0.7% -$9.75K ﹤0.01% 1715
2020
Q3 		$1.15M Sell
14,588
-822
-5% -$67K ﹤0.01% 1738
2020
Q2 		$1.11M Buy
15,410
+71
+0.5% +$4.94K ﹤0.01% 1739
2020
Q1 		$878K Buy
15,339
+170
+1% +$15.7K ﹤0.01% 1758
2019
Q4 		$1.7M Buy
15,169
+1,070
+8% +$114K ﹤0.01% 1665
2019
Q3 		$1.36M Buy
14,099
+138
+1% +$13K ﹤0.01% 1683
2019
Q2 		$1.2M Buy
13,961
+101
+0.7% +$8.3K ﹤0.01% 1776
2019
Q1 		$1.15M Buy
13,860
+70
+0.5% +$5.09K ﹤0.01% 1783
2018
Q4 		$885K Buy
13,790
+2,142
+18% +$147K ﹤0.01% 1847
2018
Q3 		$923K Sell
11,648
-55
-0.5% -$4.25K ﹤0.01% 1906
2018
Q2 		$857K Buy
11,703
+29
+0.2% +$1.97K ﹤0.01% 1906
2018
Q1 		$739K Buy
11,674
+54
+0.5% +$3.22K ﹤0.01% 1915
2017
Q4 		$592K Sell
11,620
-10
-0.1% -$521 ﹤0.01% 2025
2017
Q3 		$610K Hold
11,630
– – ﹤0.01% 2013
2017
Q2 		$592K Sell
11,630
-410
-3% -$20.3K ﹤0.01% 1990
2017
Q1 		$535K Hold
12,040
– – ﹤0.01% 2036
2016
Q4 		$532K Sell
12,040
-2,760
-19% -$117K ﹤0.01% 2016
2016
Q3 		$593K Buy
14,800
+2,800
+23% +$119K ﹤0.01% 1943
2016
Q2 		$573K Hold
12,000
– – ﹤0.01% 1910
2016
Q1 		$503K Buy
12,000
+380
+3% +$14.9K ﹤0.01% 1970
2015
Q4 		$512K Buy
11,620
+1,970
+20% +$85.5K ﹤0.01% 1947
2015
Q3 		$461K Hold
9,650
– – ﹤0.01% 1989
2015
Q2 		$562K Hold
9,650
– – ﹤0.01% 1950
2015
Q1 		$487K Hold
9,650
– – ﹤0.01% 1988
2014
Q4 		$434K Hold
9,650
– – ﹤0.01% 2016
2014
Q3 		$356K Hold
9,650
– – ﹤0.01% 2083
2014
Q2 		$426K Hold
9,650
– – ﹤0.01% 2013
2014
Q1 		$419K Hold
9,650
– – ﹤0.01% 1993
2013
Q4 		$410K Hold
9,650
– – ﹤0.01% 1996
2013
Q3 		$328K Buy
9,650
+500
+5% +$16.3K ﹤0.01% 2078
2013
Q2 		$286K Buy
+9,150
New +$297K ﹤0.01% 2083

Other funds holding CNMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

T. Rowe Price Associates's CNMD Position: Q1 2026 in Review

T. Rowe Price Associates reduced its CONMED (CNMD) stake by 77% in Q1 2026, selling an estimated $4.99M and leaving 36,088 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2027.

T. Rowe Price Associates first reported a position in CNMD in Q2 2013 and has held it in 52 quarters since. The position peaked at $40.1M in Q2 2023. 236 funds tracked by Wall St. Rank hold CNMD as of Q1 2026.

  • T. Rowe Price Associates held 36,088 shares of CONMED worth $1.28M as of Q1 2026.
  • T. Rowe Price Associates sold 122,640 CONMED shares in Q1 2026, an estimated $4.99M.
  • CONMED made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2027 holding.
  • T. Rowe Price Associates first reported a position in CONMED in Q2 2013 and has held it in 52 quarters since.
  • T. Rowe Price Associates's CONMED position peaked at $40.1M in Q2 2023.
  • 236 funds tracked by Wall St. Rank held CONMED as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.